{
    "success": true,
    "data": {
        "id": 1841817,
        "msgid": "tirzepatide-therapy-innovation-officially-launched-in-indonesia-for-type-2-diabetes-and-obesity-1783248711",
        "date": "2026-07-05 17:19:00",
        "title": "Tirzepatide Therapy Innovation Officially Launched in Indonesia for Type 2 Diabetes and Obesity",
        "author": "Basuki Eka Purnama",
        "source": "MEDIA_INDONESIA",
        "tags": "",
        "topic": "Health",
        "summary": "A new evidence-based therapy for type 2 diabetes and obesity, tirzepatide, has been officially introduced in Indonesia. The drug, a first-in-class dual GIP and GLP-1 receptor agonist, aims to address the country's growing metabolic health crisis, where diabetes cases are projected to reach 28.6 million by 2050. Its launch was facilitated by a fast-track evaluation from the Indonesian Food and Drug Authority (BPOM).",
        "content": "<p>A new evidence-based therapy option for managing type 2 diabetes\nmellitus and obesity has officially arrived in Indonesia with the\nintroduction of tirzepatide. This medical innovation is the\nfirst-in-class dual glucose-dependent insulinotropic polypeptide (GIP)\nand glucagon-like peptide-1 (GLP-1) receptor agonist, expected to\naddress the nation\u2019s rising metabolic health challenges. Type 2 diabetes\nand obesity are closely linked conditions. According to the\nInternational Diabetes Federation (IDF) Diabetes Atlas 2025, an\nestimated 20.4 million adults in Indonesia are living with diabetes, a\nfigure projected to surge to 28.6 million by 2050. Meanwhile, the 2023\nIndonesian Health Survey (SKI) recorded that the prevalence of adult\nobesity has reached 23.4 percent, a significant increase that heightens\nthe risk of serious complications such as cardiovascular and chronic\nkidney disease. PT Anugerah Pharmindo Lestari (APL), a Zuellig Pharma\ncompany, announced the availability of tirzepatide. Christophe Piganiol,\nPresident Director of APL, stated that this step is part of the\ncompany\u2019s effort to bring impactful health innovations to the Indonesian\npublic. \u2018The arrival of tirzepatide is an important step in our efforts\nto bring impactful health innovations to the Indonesian public and\nensure more patients can gain access to appropriate therapy,\u2019 said\nChristophe Piganiol. The therapy\u2019s entry into the domestic market was\nalso supported by an efficient regulatory process. Through a fast-track\nevaluation pathway from the Indonesian Food and Drug Authority (BPOM),\nthis therapy can be accessed earlier by patients in need. APL is\ncommitted to collaborating with medical professional organisations and\nhealthcare workers to ensure optimal education and distribution of this\ntherapy. With its dual mechanism of action targeting GIP and GLP-1\nreceptors, tirzepatide offers a more comprehensive approach to managing\nblood sugar levels while simultaneously aiding weight management in\nobese patients. The presence of this innovation is expected to improve\npatients\u2019 quality of life and reduce the national health burden from\nnon-communicable diseases in the future.<\/p>",
        "url": "https:\/\/jawawa.id\/newsitem\/tirzepatide-therapy-innovation-officially-launched-in-indonesia-for-type-2-diabetes-and-obesity-1783248711",
        "image": ""
    },
    "sponsor": "Okusi Associates",
    "sponsor_url": "https:\/\/okusiassociates.com"
}